Evidence map›Paper›PMID 27421985›Full record

ArticleBiochimica et biophysica acta2016

Class I PI3-kinase or Akt inhibition do not impair axonal polarization, but slow down axonal elongation.

Héctor Diez, Ma José Benitez, Silvia Fernandez, Ignacio Torres-Aleman, Juan José Garrido, Francisco Wandosell

Abstract read
PubMed Publisher
In one paragraph

Article in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Héctor DiezCentro de Biología Molecular "Severo Ochoa", CSIC-UAM, Univ. Autonoma de Madrid, 28049 Madrid, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
Ma José BenitezCentro de Biología Molecular "Severo Ochoa", CSIC-UAM, Univ. Autonoma de Madrid, 28049 Madrid, Spain; Dept. Quimica Fisica Aplicada, Univ. Autonoma de Madrid, Madrid 28049, Spain; Department of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal, CSIC, Spain.
Silvia FernandezDepartment of Functional and Systems Neurobiology, Instituto Cajal, CSIC, Madrid 28002, Spain.
Ignacio Torres-AlemanDepartment of Functional and Systems Neurobiology, Instituto Cajal, CSIC, Madrid 28002, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain.
Juan José GarridoDepartment of Molecular, Cellular and Developmental Neurobiology, Instituto Cajal, CSIC, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain. Electronic address: jjgarrido@cajal.csic.es.
Francisco WandosellCentro de Biología Molecular "Severo Ochoa", CSIC-UAM, Univ. Autonoma de Madrid, 28049 Madrid, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain. Electronic address: fwandosell@cbm.csic.es.
Centro de Biología Molecular Severo Ochoa · ESInstituto Cajal · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESCentro de Investigación Biomédica en Red · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PI3K proteins family have multiple and essential functions in most cellular events. This family is composed of class I, class II and class III PI3Ks, which upstream and downstream elements are not completely elucidated. Previous studies using the broad PI3K inhibitor, LY294002 allowed to propose that PI3 kinase>Akt pathway is a key element in the determination of axonal polarity in hippocampal neurons. Recently, new inhibitors with a higher selectivity for class I PI3K have been characterized. In the present study we have examined this widely accepted theory using a new class I PI3K inhibitor (GDC-0941), as well as Akt inhibitors, and PTEN phosphatase constructs to reduce PIP3 levels. Our present data show that both, class I PI3K inhibitor and Akt inhibitor did not alter axon specification in hippocampal neurons, but greatly reduced axon length. However, in the same experiments LY294002 effectively impeded axonal polarization, as previously reported. Our biochemical data show that both, class I PI3K and Akt inhibitors, effectively block downstream elements from Akt to S6K1 activity. Both inhibitors are stable in culture medium along the time period analysed, maintaining the inhibition better than LY294002. Besides, we found evidence that LY294002 directly inhibits mTORC1. However, further analysis using an mTORC1 inhibitor showed no change in neuron polarity. Same result was obtained using a general class III PI3K inhibitor. Interestingly, we found that either, wild-type PTEN, or a phosphatase-dead form of PTEN, disrupted axonal polarization, strongly suggesting that the role of PTEN in axonal polarity can be independent of PIP3.

Indexed as

AnimalsAxonsCell Line, TumorCell PolarityCell SurvivalCerebral CortexChromonesClass I Phosphatidylinositol 3-KinasesDose-Response Relationship, DrugGestational AgeHippocampusIndazolesMechanistic Target of Rapamycin Complex 1MiceMorpholinesMultiprotein Complexes2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineChromonesClass I Phosphatidylinositol 3-KinasesIndazolesLY 290042Mechanistic Target of Rapamycin Complex 1MorpholinesMultiprotein ComplexesPhosphatidylinositol PhosphatesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseSulfonamidesTOR Serine-Threonine KinasesAktAxon establishmentmTORC1PI3KPolaritySignalling

Identifiers

PMID27421985
OpenAlexW2468767371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.